Filter
2912
Filtered Results: 2912
Text search:
heart
diseases
Featured
Recommendations
303
New Publications
636
Language
Document type
No document type
1400
Studies & Reports
579
Guidelines
410
Manuals
184
Fact sheets
98
Strategic & Response Plan
84
Training Material
72
Situation Updates
20
Infographics
19
Brochures
17
Resource Platforms
13
Dashboards/Maps
6
Videos
5
Online Courses
4
App
1
Countries / Regions
Global
184
India
171
South Africa
81
Kenya
73
Ethiopia
62
Latin America and the Carribbean
54
Western and Central Europe
51
Uganda
44
Africa
43
Philippines
42
Bangladesh
41
Sierra Leone
39
Nepal
38
Nigeria
37
Liberia
36
Zambia
35
Myanmar / Burma
34
Ghana
28
Ukraine
28
Rwanda
26
Indonesia
26
Tanzania
25
Malawi
24
South–East Asia Region
24
Brazil
22
Syria
20
Namibia
20
Russia
20
Asia
18
Eastern Europe
18
Lesotho
13
Middle East and North Africa
13
South Sudan
12
Cambodia
12
Mozambique
12
West and Central Africa
12
Guinea
11
Congo, Democratic Republic of
11
Haiti
11
Germany
11
East and Southern Africa
11
Venezuela
11
Western Pacific Region
10
Eastern Europe and Central Asia
10
North America
10
Botswana
9
Senegal
8
USA
8
Zimbabwe
8
Eswatini/ Swaziland
7
Colombia
7
Vietnam
7
Papua New Guinea
6
Cameroon
5
Afghanistan
5
Lebanon
5
Argentina
5
Peru
5
Chile
5
Yemen
5
Somalia
4
Pakistan
4
Thailand
4
Laos
4
Moldova
4
Kyrgyzstan
4
United Kingdom
4
Burkina Faso
3
China
3
Sudan
3
Central African Republic
3
Ecuador
3
Bolivia
3
Mexico
3
Paraguay
3
Jamaica
3
Spain
3
Iraq
2
Jordan
2
Malaysia
2
Benin
2
North Macedonia
2
Switzerland
2
Angola
2
Sri Lanka
2
Other region
2
Fiji
2
Bhutan
2
Albania
2
Mongolia
2
Tajikistan
2
Kazakhstan
2
Georgia
2
Guinea-Bissau
1
Niger
1
Turkey
1
Egypt
1
Gambia
1
Ireland
1
Singapore
1
Hungary
1
Honduras
1
Greece
1
Libya
1
Guatemala
1
Bahamas
1
Poland
1
Southern Africa
1
Canada
1
Romania
1
Lithuania
1
Slovakia
1
Mauritius
1
Portugal
1
South Korea
1
Azerbaijan
1
Belarus
1
French Guyana
1
Israel
1
Bosnia and Herzegovina
1
Latvia
1
Authors & Publishers
Publication Years
Category
Countries
1034
Clinical Guidelines
324
Public Health
303
Women & Child Health
168
Capacity Building
93
Key Resources
78
Pharmacy & Technologies
10
Annual Report MEDBOX
1
Toolboxes
Mental Health
285
COVID-19
284
NCDs
282
Planetary Health
149
Caregiver
115
HIV
105
Disability
85
TB
78
NTDs
74
Global Health Education
73
Ebola
65
Conflict
55
Refugee
55
Pharmacy
55
Rapid Response
48
AMR
40
Natural Hazards
24
Social Ethics
24
Health Financing Toolbox
17
Zika
15
Cholera
12
Polio
10
Specific Hazards
8
Global Hear, March 2014, Vol. 9 no.1
Chagas disease is found mainly in endemic areas of 21 continental Latin American countries. The most common way people are infected with Chagas is through the blood-sucking triatomine bugs, also known as ‘kissing bugs’ (or vinchuca, barbeiro, pi...
Unpreparedness of health professionals to address non-communicable diseases (NCD) at peripheral health facilities is a critical health system challenge in Mozambique. To address this weakness and decentralize NCD care, training of the primary care w...
Peripheral artery disease is similar to coronary artery disease (CAD).
Peripheral artery disease is a narrowing of the peripheral arteries that ca...
In 2014, the World Heart Federation (WHF) launched
an initiative to develop a series of Roadmaps [1e6]. Their
aim is to identify potential roadblocks on the pathway to
effective prevention, detection, and management of cardiovascular ... (CVD), along with evidence-based
solutions to overcome them. The resulting documents
provide a framework to translate strategic intent into action
on integrating epidemiology, population, and cardiovascular outcome trial data into national plans for optimal
CVD management.
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart...
Treatment plan
Background
Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordability of cardiovascular ... and hypertension medicines to identify areas for improvement in access to medication treatment.
Methods and Results
We used the World Health Organization online repository of national essential medicines lists (EMLs) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest‐price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low‐ and lower‐middle‐income countries and 60% in high‐ and upper‐middle‐income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low‐ and lower‐middle‐income countries compared with high‐ and upper‐middle‐income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days’ wage for brand medicine and 1.8 days’ wage for generics. Affordability was lower in low‐ and lower‐middle‐income countries than high‐ and upper‐middle‐income countries for both brand and generic medications.
Conclusions
The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low‐ and lower‐middle‐income countries.
Objective: To conduct a landscape assessment of public knowledge of cardiovascular disease risk factors and acute myocardial infarction symptoms, cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) awareness and training i...
The WHF IASC Roadmap proposes strategies and evidence-based solutions for healthcare professionals, health authorities and governments to help overcome the barriers to comprehensive care for Chagas disease patients. This roadmap describes an ideal p...
A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' ... have now been detected in non-endemic areas, such as North America and some European countries. This parasitic zoonosis, caused by Trypanosoma cruzi, is transmitted to humans by infected Triatominae insects, or occasionally by non-vectorial mechanisms, such as blood transfusion, mother to fetus, or oral ingestion of materials contaminated with parasites. Following the acute phase of the infection, untreated individuals enter a chronic phase that is initially asymptomatic or clinically unapparent. Usually, a few decades later, 40-50% of patients develop progressive cardiomyopathy and/or motility disturbances of the oesophagus and colon. In the last decades several interventions targeting primary, secondary and tertiary prevention of Chagas' disease have been attempted. While control of both vectorial and blood transfusion transmission of T cruzi (primary prevention) has been successful in many regions of Latin America, early detection and aetiological treatment of asymptomatic subjects with Chagas' disease (secondary prevention) have been largely underutilised. At the same time, in patients with established chronic disease, several pharmacological and non-pharmacological interventions are currently available and have been increasingly used with the intention of preventing or delaying complications of the disease (tertiary prevention). In this review we discuss in detail each of these issues.
Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the ...
In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases
(NCD). This commitment was echoed in 2015 by the United Nations Sustainable Development Goals...
Global progress against cardiovascular disease (CVD) is flatlining.
Though rates of CVD deaths globally have fallen in the last three
decades, this trend has begun to stall and, without concerted
efforts, is at risk of reversing.
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and hea...
The World Heart Federation (WHF) Roadmap series covers a large range of cardiovascular conditions. These Roadmaps identify potential roadblocks and their solutions to improve the prevention, detection and management of cardiovascular ... and provide a generic global framework available for local adaptation. A first Roadmap on raised blood pressure was published in 2015. Since then, advances in hypertension have included the publication of new clinical guidelines (AHA/ACC; ESC; ESH/ISH); the launch of the WHO Global HEARTS Initiative in 2016 and the associated Resolve to Save Lives (RTSL) initiative in 2017; the inclusion of single-pill combinations on the WHO Essential
Medicines’ list as well as various advances in technology, in particular telemedicine and mobile health. Given the substantial benefit accrued from effective interventions in the management of hypertension and their potential for scalability in low and middle-income countries (LMICs), the WHF has now revisited and updated the ‘Roadmap for raised BP’ as ‘Roadmap for hypertension’
by incorporating new developments in science and policy. Even though cost-effective lifestyle and medical interventions to prevent and manage hypertension exist, uptake is still low, particularly in resource-poor areas. This Roadmap examined the roadblocks pertaining to both the demand side (demographic and socio-economic factors, knowledge and beliefs, social relations, norms, and
traditions) and the supply side (health systems resources and processes) along the patient pathway to propose a range of possible solutions to overcoming them. Those include the development of population-wide prevention and control programmes; the implementation of opportunistic screening and of out-of-office blood pressure measurements; the strengthening of primary care and a greater focus on task sharing and team-based care; the delivery of people-centred care and stronger patient and carer education; and the facilitation of adherence to treatment. All of the above are dependent upon the availability and effective distribution of good quality, evidencebased, inexpensive BP-lowering agents.
Cardiovascular diseases are the world’s leading cause of disability and death. Such diseases were responsible in 2019 for an estimated 18.6 million deaths globally and 957,000 deaths in the United...
Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
